fluphenazine and Schizophrenia studies

Schizophrenia: A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.

Research Excerpts

Excerpt	Relevance	Reference
"This study was undertaken to evaluate the efficacy and safety of olanzapine compared with fluphenazine in the treatment of patients who met the Diagnostic and Statistical Manual, fourth edition (DSM-IV) diagnostic criteria for schizophrenia or schizoaffective disorder."	9.11	Double-blind, randomized comparison of olanzapine versus fluphenazine in the long-term treatment of schizophrenia. ( Dossenbach, MR; Folnegovic-Smalc, V; Friedel, P; Grundy, SL; Hotujac, L; Jakovljevic, MM; Tollefson, GD; Uglesic, B, 2004)
"Thyroid function was assessed in 38 adult DSM-IV-diagnosed schizophrenia patients after 6 weeks of prospective, double-blind, randomized treatment with quetiapine (400 mg/day), risperidone (4 mg/day), or fluphenazine (12."	9.11	Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine. ( Conley, RR; Kelly, DL, 2005)
"Efficacy data support the use of diazepam in treating prodromal and early warning signs of symptom exacerbation in schizophrenia."	9.09	Diazepam treatment of early signs of exacerbation in schizophrenia. ( Breier, AF; Buchanan, RW; Carpenter, WT; Kirkpatrick, B, 1999)
"The regional cerebral glucose metabolic rates of clozapine-treated and fluphenazine-treated women with schizophrenia and normal controls were obtained by positron emission tomography (PET) using [18F]-2-fluoro-2-deoxy-D-glucose (FDG) as the tracer."	9.09	The brain metabolic patterns of clozapine- and fluphenazine-treated female patients with schizophrenia: evidence of a sex effect. ( Cohen, RM; Nordahl, TE; Pickar, D; Semple, WE, 1999)
"Fluphenazine levels, side effects, depression and psychosocial outcome were measured at five time points over approximately 1 year in 59 recent onset schizophrenic patients treated with a maintenance dose of injectable fluphenazine decanoate."	9.09	Fluphenazine levels during maintenance treatment of recent-onset schizophrenia: relation to side effects, psychosocial function and depression. ( Aravagiri, M; Bartzokis, G; Fogelson, D; Gitlin, MJ; Mintz, J; Nuechterlein, KH; Subotnik, K; Ventura, J, 2000)
"We investigated whether antagonism of alpha 2 adrenergic receptors would augment treatment response in schizophrenia, by administering idazoxan, an alpha 2 antagonist drug, to treatment-resistant patients on typical neuroleptics."	9.08	Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine. ( Hong, WW; Litman, RE; Pickar, D; Potter, WZ; Su, TP, 1996)
"This study was conducted to determine whether the addition of naltrexone to ongoing neuroleptic treatment would facilitate the reduction in positive or negative symptoms in patients with schizophrenia."	9.08	Naltrexone augmentation of neuroleptics in schizophrenia. ( Charney, DS; Glazer, WM; Heninger, GR; Krystal, JH; Petrakis, IL; Price, LH; Sernyak, MJ; Woods, SW, 1998)
"The introduction of the atypical neuroleptic, clozapine, has had widespread influence not only on the treatment of the seriously mentally ill patient, but also on new drug development and on hypotheses of the pathophysiology of schizophrenia."	9.07	Predictors of clozapine response in schizophrenia. ( Hsiao, JK; Litman, RE; Owen, RR; Pickar, D; Su, TP, 1994)
"These results demonstrate that clozapine treatment has potent serotonin antagonist effects in patients with schizophrenia."	9.07	Effects of clozapine and fluphenazine treatment on responses to m-chlorophenylpiperazine infusions in schizophrenia. ( Benkelfat, C; Gutierrez-Esteinou, R; Hadd, K; Hsiao, J; Lawlor, BA; Murphy, DL; Owen, RR; Pickar, D, 1993)
"Twenty-one patients with schizophrenia who met criteria for neuroleptic treatment resistance or intolerance participated in a crossover, placebo-controlled, double-blind comparison of long-term typical neuroleptic and clozapine treatment."	9.07	Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine. ( Gutierrez, R; Konicki, E; Litman, RE; Owen, RR; Pickar, D; Rapaport, MH, 1992)
"A 1 year double-blind trial of bromperidol decanoate and fluphenazine decanoate was conducted in the maintenance treatment of 47 outpatients with schizophrenia."	9.07	Positive and negative symptoms, depression and social disability in chronic schizophrenia: a comparative trial of bromperidol and fluphenazine decanoates. ( Cookson, JC; McLaren, S; Silverstone, T, 1992)
"The efficacy of the use of moditen-depo and haloperidol decanoate as preventive anti-recurrence+ therapy was studied and compared in 2 groups of patients suffering from attack-like schizophrenia with frequent exacerbations."	9.06	[Clinical and economic approach to evaluation of the effectiveness of moditen-depot and haloperidol decanoate in the maintenance therapy of attack-like schizophrenia]. ( Kalugina, LI; Kopeĭko, GI; Kravchenko, NE; Mirzoian, MG; Ushakov, IuV, 1990)
"Plasma homovanillic acid (HVA) levels were measured hourly for a 24-hour period in 10 patients with schizophrenia during treatment with placebo and fluphenazine."	9.06	Circadian variation of plasma homovanillic acid levels is attenuated by fluphenazine in patients with schizophrenia. ( Doran, AR; Douillet, P; Labarca, R; Pickar, D; Roy, A; Wolkowitz, OM, 1990)
"This paper reports a randomized, controlled, partially-blinded, flexible dose, parallel group, comparative study of the efficacy and tolerance of pipothiazine palmitate and fluphenazine decanoate in patients in remission from Schizophrenia over a 28 week period."	9.06	A comparative study of pipothiazine palmitate and fluphenazine decanoate in the maintenance of remission of schizophrenia. ( Gill, RC; Leong, OK; Tay, WK; Wong, KE, 1989)
" A controlled clinical trial has shown oral pimozide to be clinically at least as effective as fluphenazine decanoate in the continuation treatment of schizophrenia."	9.04	Medico-social evaluation of the long-term pharmacotherapy of schizophrenia. Comparative study of fluphenazine and pimozide. ( Shepherd, M, 1979)
"To compare the effects of oral fluphenazine with placebo for the treatment of schizophrenia."	8.98	Fluphenazine (oral) versus placebo for schizophrenia. ( Almerie, MQ; Matar, HE; Sampson, SJ, 2018)
"To measure the outcomes (both beneficial and harmful) of the clinical effectiveness, safety and cost-effectiveness of oral fluphenazine versus atypical antipsychotics for schizophrenia."	8.93	Fluphenazine (oral) versus atypical antipsychotics for schizophrenia. ( Furtado, VA; Li, BG; Sampford, JR; Sampson, S; Xia, J; Zhao, S, 2016)
"To assess the effects of fluphenazine decanoate and enanthate versus oral anti-psychotics and other depot neuroleptic preparations for individuals with schizophrenia in terms of clinical, social and economic outcomes."	8.91	Fluphenazine decanoate (depot) and enanthate for schizophrenia. ( Adams, CE; Asher, R; David, A; Eisenbruch, M; Jayaswal, A; Maayan, N; Quraishi, SN; Rathbone, J, 2015)
"To review the effects of fluphenazine and low-potency antipsychotics for people with schizophrenia."	8.90	Fluphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia. ( Engel, RR; Huhn, M; Leucht, S; Tardy, M, 2014)
"To compare the effects of oral fluphenazine with placebo for the treatment of schizophrenia."	8.89	Fluphenazine (oral) versus placebo for schizophrenia. ( Almerie, MQ; Matar, HE; Sampson, S, 2013)
"To evaluate the effects of oral fluphenazine for schizophrenia in comparison with placebo."	8.84	Oral fluphenazine versus placebo for schizophrenia. ( Almerie, MQ; Matar, HE, 2007)
"We considered all relevant randomised clinical controlled trials focusing on people with schizophrenia comparing fluphenazine decanoate or enanthate with placebo or oral anti-psychotics or other depot preparations."	8.82	Depot fluphenazine decanoate and enanthate for schizophrenia. ( Adams, CE; David, A; Eisenbruch, M; Quraishi, S; Rathbone, J, 2005)
"To compare depot fluphenazine medication to oral fluphenazine for treatment of schizophrenia."	8.80	Depot fluphenazine for schizophrenia. ( Adams, CE; Eisenbruch, M, 2000)
" This study aimed to report a case with bradycardia induced by fluphenazine decanoate administration."	8.12	Fluphenazine decanoate-induced bradycardia: A case report. ( Azizi, M; Elyasi, F; Kamali, M; Zarghami, M, 2022)
"This study compares 3 cohorts of patients with schizophrenia before, during, and after initiating treatment with fluphenazine decanoate (FD), haloperidol decanoate (HD), or long-acting injectable risperidone (LAR)."	7.74	Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone. ( Ascher-Svanum, H; Marcus, SC; Olfson, M, 2007)
"To report a case of neuroleptic malignant syndrome (NMS) associated with fluphenazine in a schizophrenic patient and review the literature related to this condition."	7.73	Fluphenazine-induced neuroleptic malignant syndrome in a schizophrenic patient. ( Aruna, AS; Murungi, JH, 2005)
"The authors' goal was to explore whether clozapine given as the first antipsychotic treatment favorably affects the course of schizophrenia."	7.72	Clozapine as a first treatment for schizophrenia. ( Alvir, JM; Kane, JM; Lieberman, JA; Robinson, DG; Sheitman, BB; Woerner, MG, 2003)
"On one of our rehabilitation wards, we observed several schizophrenic patients with therapy resistant hallucinations to exhibit complete recovery after being given fluphenazine (2-7."	7.69	[Is there a special indication for fluphenazine in therapy refractory hallucinations?]. ( Bechter, K, 1994)
"The regional cerebral glucose metabolic rates of patients with schizophrenia who were and were not receiving neuroleptic drugs and normal control subjects were obtained by positron emission tomography using fludeoxyglucose F 18 as the tracer."	7.69	The brain metabolic patterns of clozapine- and fluphenazine-treated patients with schizophrenia during a continuous performance task. ( Andreason, P; Cohen, RM; Litman, RE; Nordahl, TE; Pickar, D; Semple, WE, 1997)
"Alprazolam, when added under double-blind conditions to a stable neuroleptic regimen in two patients with schizophrenia, resulted in clinically apparent improvement in positive and negative schizophrenic symptoms."	7.67	Combination alprazolam-neuroleptic treatment of the positive and negative symptoms of schizophrenia. ( Breier, A; Doran, AR; Paul, SM; Pickar, D; Tarell, J; Wolkowitz, OM, 1986)
"Neuropeptide Y (a recently discovered brain peptide that is colocalized with norepinephrine within some adrenergic central nervous system neurons) was measured in the cerebrospinal fluid (CSF) from patients with major affective disorder, chronic schizophrenia, and in normal volunteers."	7.67	Cerebrospinal fluid neuropeptide Y in depression and schizophrenia. ( Berrettini, WH; Doran, AR; Kelsoe, J; Pickar, D; Roy, A, 1987)
"A chronic schizophrenic patient received 30 mg fluphenazine hydrochloride (Prolixin) PO and developed priapism."	7.67	Priapism resulting from fluphenazine hydrochloride treatment reversed by diphenhydramine. ( Fishbain, DA, 1985)
"The management of an agitated schizophrenic was complicated by the onset of severe hepatocellular dysfunction concomitant with the administration of fluphenazine, a drug which has rarely been implicated in phenothiazine jaundice."	7.66	Fluphenazine jaundice. Report of a case. ( Snyder, S, 1980)
"Treatment with olanzapine moderately decreased, while treatment with fluphenazine significantly increased plasma cortisol levels and muscle rigidity."	6.73	The effects of olanzapine and fluphenazine on plasma cortisol, prolactin and muscle rigidity in schizophrenic patients: a double blind study. ( Jakovljevic, M; Ljubicic, D; Marcinko, D; Mihaljevic-Peles, A; Muck-Seler, D; Mustapic, M; Pivac, N; Relja, M, 2007)
" Results suggested an absorption half-life of 4 weeks, although, in three cases steady state was only achieved after 11 monthly injections."	6.67	Pharmacokinetics of haloperidol and fluphenazine decanoates in chronic schizophrenia. ( McCreadie, RG; Whitehead, A; Wiles, DH, 1990)
" The dosage equivalency of haloperidol decanoate (1."	6.66	A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia. ( Annable, L; Campbell, W; Chouinard, G, 1989)
"Issues regarding the side effects of antipsychotic medication and the possible contribution of the environment to dose requirements led to a two-year controlled dosage study of maintenance antipsychotic medication and familial environment among recently discharged schizophrenic patients."	6.66	Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Results of a two-year controlled study. ( Bartone, P; Carter, M; Cather, R; Cooley, SJ; DiBarry, AL; Hogarty, GE; Madonia, MJ; McEvoy, JP; Munetz, M; Ulrich, RF, 1988)
" The results suggest that lower doses of fluphenazine decanoate than those usually used may be effective in preventing psychotic relapse while keeping total cumulative dosage to a minimum."	6.65	Low dose fluphenazine decanoate in maintenance treatment of schizophrenia. ( Kane, JM; Klein, DF; Nayak, D; Quitkin, F; Ramos-Lorenzi, JR; Rifkin, A; Sachar, EJ; Saraf, K, 1979)
"/day) versus fixed standard dosage (20 mg."	6.64	High vs standard dosage fluphenazine HCL in acute schizophrenia. ( Donlon, PT; Meadow, A; Tupin, JP; Wahba, M, 1978)
"Benztropine was prescribed only if needed and was administered to 65% of patients."	6.64	The initiation of long-term pharmacotherapy in schizophrenia: dosage and side effect comparisons between oral and depot fluphenazine. ( Levine, J; Schooler, NR, 1976)
"Fluphenazine is an inexpensive and widely accessible antipsychotic drug that has been available to treat people with schizophrenia for five decades."	6.49	Fluphenazine (oral) versus placebo for schizophrenia. ( Almerie, MQ; Matar, HE; Sampson, S, 2013)
"Co-occurring substance use disorders (SUD), including alcohol, are common in schizophrenia (SZ) and are associated with poor outcome."	5.40	Schizophrenia and co-occurring substance use disorder: reward, olfaction and clozapine. ( Gibson, LE; Green, AI; Mesholam-Gately, RI; Seidman, LJ, 2014)
"Fluphenazine was significantly effective in treating symptoms such as emotional withdrawal, blunted affect, suspiciousness, thought disturbances, but not hallucinations."	5.28	Clinical and toxicological profile of fluphenazine decanoate in elderly chronic schizophrenia. ( Altamura, AC; Girardi, T; Mauri, MC; Panetta, B, 1990)
" Based on the study of plasma levels achieved with FPZ-D injection and oral FPZ-H (fluphenazine HC1) in 6 patients, the dosage requirement of FPZ-D appeared to be difficult to predict from the oral dosage of FPZ-H in the same patient."	5.27	Plasma levels of fluphenazine during fluphenazine decanoate treatment in schizophrenia. ( Casper, RC; Chang, SS; Davis, JM; Dysken, MW; Janicak, PG; Javaid, JI, 1985)
" The clinical effectivity came up to the usual therapy with normal high dosage after 28 days therapy, a somewhat more rapid deliverance of symptoms during the first days remained impressive."	5.26	High dosage treatment with fluphenazine intravenously followed by depot injections in acute schizophrenia. ( Fleischhauer, J, 1980)
" (2) It allows a diminution of the maintenance dosage and thereby reduces the occurrence of side-effects and furthermore the danger of the chemo-toxic damaging of a series of inner organs and systems."	5.25	[Depot fluphenazine as a means of stabilizing remission in cases of schizophrenia]. ( Vovin, RIa; Vovina, EN, 1975)
"From December 2004 through March 2008, adult outpatients with a Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition diagnosis of schizophrenia or schizoaffective disorder who were taking haloperidol decanoate (n = 40) or fluphenazine decanoate (n = 22) were randomly assigned to stay on current long-acting injectable medication or switch to risperidone microspheres and followed for 6 months under study protocol and an additional 6 months naturalistic follow-up."	5.16	Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial. ( Covell, NH; Essock, SM; Jackson, CT; McEvoy, JP; Rojas, IA; Schooler, NR; Stroup, TS, 2012)
"Eighty hospitalized patients suffering from Schizophrenia or Schizoaffective disorder (male 54, female 26) were first treated with Haloperidol (N=60) or Fluphenazine (N=20), and then were switched to Risperidone."	5.15	First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients. ( Popović, I; Popović, V; Ravanić, D; Stanojević, A; Stojanović, M; Vladejić, S, 2011)
"This study was undertaken to evaluate the efficacy and safety of olanzapine compared with fluphenazine in the treatment of patients who met the Diagnostic and Statistical Manual, fourth edition (DSM-IV) diagnostic criteria for schizophrenia or schizoaffective disorder."	5.11	Double-blind, randomized comparison of olanzapine versus fluphenazine in the long-term treatment of schizophrenia. ( Dossenbach, MR; Folnegovic-Smalc, V; Friedel, P; Grundy, SL; Hotujac, L; Jakovljevic, MM; Tollefson, GD; Uglesic, B, 2004)
"Long-acting injectable risperidone was assessed in schizophrenia patients who were symptomatically stable on conventional depot antipsychotics and who were then switched to long-acting risperidone."	5.11	Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. ( Eerdekens, E; Eerdekens, M; Jacko, M; Turner, M, 2004)
"Thyroid function was assessed in 38 adult DSM-IV-diagnosed schizophrenia patients after 6 weeks of prospective, double-blind, randomized treatment with quetiapine (400 mg/day), risperidone (4 mg/day), or fluphenazine (12."	5.11	Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine. ( Conley, RR; Kelly, DL, 2005)
" With this in mind, we evaluated the usefulness of monitoring fluphenazine plasma levels for patients with schizophrenia who were receiving maintenance treatment with fluphenazine decanoate."	5.10	Fluphenazine plasma level monitoring for patients receiving fluphenazine decanoate. ( Aravagiri, M; Lebell, M; Marder, SR; Mintz, J; Wirshing, DA; Wirshing, WC, 2002)
"Efficacy data support the use of diazepam in treating prodromal and early warning signs of symptom exacerbation in schizophrenia."	5.09	Diazepam treatment of early signs of exacerbation in schizophrenia. ( Breier, AF; Buchanan, RW; Carpenter, WT; Kirkpatrick, B, 1999)
"Fifty outpatients with schizophrenia or schizoaffective disorder were randomly assigned to receive 25 mg of fluphenazine decanoate intramuscularly either every 2 weeks or every 6 weeks for 54 weeks in a double-blind design."	5.09	Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks. ( Breier, AF; Buchanan, RW; Carpenter, WT; Kirkpatrick, B; Lann, HD; Summerfelt, AT, 1999)
"Forty-one patients with DSM-III schizophrenia or schizoaffective disorder were assigned to either adjunctive lithium or placebo after at least 6 months of fluphenazine decanoate treatment to stabilize symptoms had failed."	5.09	Lithium augmentation fails to reduce symptoms in poorly responsive schizophrenic outpatients. ( Glick, ID; Jacobs, M; Ninan, PT; Odbert, CL; Robinson, D; Schulz, SC; Thompson, PA; Weiden, PJ; Yadalam, K, 1999)
"The regional cerebral glucose metabolic rates of clozapine-treated and fluphenazine-treated women with schizophrenia and normal controls were obtained by positron emission tomography (PET) using [18F]-2-fluoro-2-deoxy-D-glucose (FDG) as the tracer."	5.09	The brain metabolic patterns of clozapine- and fluphenazine-treated female patients with schizophrenia: evidence of a sex effect. ( Cohen, RM; Nordahl, TE; Pickar, D; Semple, WE, 1999)
"Fluphenazine levels, side effects, depression and psychosocial outcome were measured at five time points over approximately 1 year in 59 recent onset schizophrenic patients treated with a maintenance dose of injectable fluphenazine decanoate."	5.09	Fluphenazine levels during maintenance treatment of recent-onset schizophrenia: relation to side effects, psychosocial function and depression. ( Aravagiri, M; Bartzokis, G; Fogelson, D; Gitlin, MJ; Mintz, J; Nuechterlein, KH; Subotnik, K; Ventura, J, 2000)
"Effects of fluphenazine on electrodermal activity (EDA) and heart rate (HR) were studied in patients with schizophrenia and normal control subjects during rest periods, presentation of innocuous tones, and a reaction time (RT) task."	5.09	Neuroleptic effects on autonomic activity in schizophrenia: between-group and within-subject paradigms and comparisons with controls. ( Pickar, D; van Kammen, DP; Zahn, TP, 2001)
"Fifty-three volunteer patients with recent-onset schizophrenia who had been clinically stabilized on a maintenance regimen of fluphenazine decanoate for a mean of 16."	5.09	Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. ( Aravagiri, M; Bartzokis, G; Fogelson, DL; Gitlin, M; Mintz, J; Nuechterlein, K; Subotnik, KL; Ventura, J, 2001)
"We investigated whether antagonism of alpha 2 adrenergic receptors would augment treatment response in schizophrenia, by administering idazoxan, an alpha 2 antagonist drug, to treatment-resistant patients on typical neuroleptics."	5.08	Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine. ( Hong, WW; Litman, RE; Pickar, D; Potter, WZ; Su, TP, 1996)
"This study examined substance use among a group of 37 schizophrenia patients participating in a year-long fluphenazine decanoate (FD; Prolixin) dosage reduction study (Inderbitzin et al."	5.08	Substance use: a powerful predictor of relapse in schizophrenia. ( Inderbitzin, LB; Kasckow, JW; Scheller-Gilkey, G; Swofford, CD, 1996)
"Eighty male outpatients with schizophrenia were stabilized with a low dose of fluphenazine decanoate (5 to 10 mg every 14 days), which was supplemented with oral fluphenazine (5 mg twice daily) or a placebo when they first met criteria for a prodromal period."	5.08	Two-year outcome of social skills training and group psychotherapy for outpatients with schizophrenia. ( Eckman, TA; Johnston, K; Lebell, M; Liberman, RP; Marder, SR; McKenzie, J; Mintz, J; Wirshing, WC; Zimmerman, K, 1996)
"This study was conducted to determine whether the addition of naltrexone to ongoing neuroleptic treatment would facilitate the reduction in positive or negative symptoms in patients with schizophrenia."	5.08	Naltrexone augmentation of neuroleptics in schizophrenia. ( Charney, DS; Glazer, WM; Heninger, GR; Krystal, JH; Petrakis, IL; Price, LH; Sernyak, MJ; Woods, SW, 1998)
"The introduction of the atypical neuroleptic, clozapine, has had widespread influence not only on the treatment of the seriously mentally ill patient, but also on new drug development and on hypotheses of the pathophysiology of schizophrenia."	5.07	Predictors of clozapine response in schizophrenia. ( Hsiao, JK; Litman, RE; Owen, RR; Pickar, D; Su, TP, 1994)
"This study evaluated the feasibility and impact of gradually reducing relatively high doses of fluphenazine decanoate by one-half for chronically impaired, poor inner-city patients with schizophrenia."	5.07	A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients. ( Egan, GJ; Gloersen, BA; Inderbitzin, LB; Lewine, RR; Scheller-Gilkey, G; Swofford, CD; Vidanagama, BP; Waternaux, C, 1994)
"Smooth pursuit eye movement (SPEM) gain, total saccades, and subtypes of saccades were quantified from the visual pursuit tracking of 26 fluphenazine-treated patients with schizophrenia and 42 normal controls."	5.07	Quantitative effects of typical and atypical neuroleptics on smooth pursuit eye tracking in schizophrenia. ( Clem, T; Hommer, DW; Litman, RE; Pickar, D; Radant, A, 1994)
"Idazoxan, a selective alpha 2-adrenergic antagonist, was added to stable doses of fluphenazine treatment in six patients with schizophrenia who participated in a double-blind, placebo-controlled pharmacologic study."	5.07	Idazoxan, an alpha 2 antagonist, augments fluphenazine in schizophrenic patients: a pilot study. ( Hong, WW; Litman, RE; Pickar, D; Potter, WZ; Su, TP; Weissman, EM, 1993)
"These results do not indicate an association between plasma fluphenazine levels and response to treatment or extrapyramidal side effects in first-episode schizophrenia."	5.07	Relation of plasma fluphenazine levels to treatment response and extrapyramidal side effects in first-episode schizophrenic patients. ( Alvir, J; Chakos, M; Cooper, T; Kane, J; Koreen, AR; Lieberman, J; Loebel, A, 1994)
"These results demonstrate that clozapine treatment has potent serotonin antagonist effects in patients with schizophrenia."	5.07	Effects of clozapine and fluphenazine treatment on responses to m-chlorophenylpiperazine infusions in schizophrenia. ( Benkelfat, C; Gutierrez-Esteinou, R; Hadd, K; Hsiao, J; Lawlor, BA; Murphy, DL; Owen, RR; Pickar, D, 1993)
"Twenty-one patients with schizophrenia who met criteria for neuroleptic treatment resistance or intolerance participated in a crossover, placebo-controlled, double-blind comparison of long-term typical neuroleptic and clozapine treatment."	5.07	Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine. ( Gutierrez, R; Konicki, E; Litman, RE; Owen, RR; Pickar, D; Rapaport, MH, 1992)
"A 1 year double-blind trial of bromperidol decanoate and fluphenazine decanoate was conducted in the maintenance treatment of 47 outpatients with schizophrenia."	5.07	Positive and negative symptoms, depression and social disability in chronic schizophrenia: a comparative trial of bromperidol and fluphenazine decanoates. ( Cookson, JC; McLaren, S; Silverstone, T, 1992)
"Seventy-two newly readmitted, drug-free men with the diagnosis of schizophrenia by DSM-III were assigned randomly to receive fluphenazine hydrochloride at 5 mg, 10 mg, or 20 mg daily for 4 weeks."	5.07	Plasma fluphenazine levels and clinical response in newly admitted schizophrenic patients. ( Aravagiri, M; Chabert, N; Marder, SR; Mintz, J; Van Putten, T; Wirshing, WC, 1991)
"The efficacy of the use of moditen-depo and haloperidol decanoate as preventive anti-recurrence+ therapy was studied and compared in 2 groups of patients suffering from attack-like schizophrenia with frequent exacerbations."	5.06	[Clinical and economic approach to evaluation of the effectiveness of moditen-depot and haloperidol decanoate in the maintenance therapy of attack-like schizophrenia]. ( Kalugina, LI; Kopeĭko, GI; Kravchenko, NE; Mirzoian, MG; Ushakov, IuV, 1990)
"Plasma homovanillic acid (HVA) levels were measured hourly for a 24-hour period in 10 patients with schizophrenia during treatment with placebo and fluphenazine."	5.06	Circadian variation of plasma homovanillic acid levels is attenuated by fluphenazine in patients with schizophrenia. ( Doran, AR; Douillet, P; Labarca, R; Pickar, D; Roy, A; Wolkowitz, OM, 1990)
"Fifty-three patients with acute exacerbations of Research Diagnostic Criteria schizophrenic, schizoaffective (mainly schizophrenic), and other nonaffective psychoses completed 24 or 28 days of treatment with randomized, fixed, double-blind doses of 10, 20, or 30 mg of oral fluphenazine hydrochloride daily."	5.06	Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment. ( Jain, A; Levinson, DF; Silver, P; Simpson, GM; Singh, H; Stephanos, MJ; Yadalam, K, 1990)
"This paper reports a randomized, controlled, partially-blinded, flexible dose, parallel group, comparative study of the efficacy and tolerance of pipothiazine palmitate and fluphenazine decanoate in patients in remission from Schizophrenia over a 28 week period."	5.06	A comparative study of pipothiazine palmitate and fluphenazine decanoate in the maintenance of remission of schizophrenia. ( Gill, RC; Leong, OK; Tay, WK; Wong, KE, 1989)
"Alprazolam was added, under double-blind conditions, to stable fluphenazine hydrochloride regimens in 12 symptomatic, chronically ill inpatients with schizophrenia."	5.06	Alprazolam augmentation of the antipsychotic effects of fluphenazine in schizophrenic patients. Preliminary results. ( Breier, A; Doran, A; Kelsoe, J; Lucas, P; Paul, SM; Pickar, D; Wolkowitz, OM, 1988)
" All patients had been diagnosed as having schizophrenia or schizoaffective disorder, all were receiving stable doses of fluphenazine decanoate, and all had received benztropine mesylate in an attempt to rule out neuroleptic-induced akinesia."	5.06	Adjunctive imipramine in the treatment of postpsychotic depression. A controlled trial. ( Cooper, TB; Fagerstrom, R; Morgan, V; Rifkin, A; Siris, SG, 1987)
"In an attempt to begin to establish minimum effective dosage requirements for the maintenance treatment of schizophrenia, we undertook a double-blind comparison of low-dose fluphenazine decanoate (1."	5.05	Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. ( Kane, JM; Ramos-Lorenzi, J; Reardon, G; Rifkin, A; Sarantakos, S; Schiebel, D; Woerner, M, 1983)
"Sixty patients meeting the criteria established for schizophrenia who attained a clinical plateau following hospital discharge were randomized to receive for one year either penfluridol, 20 to 160 mg orally once each week, or fluphenazine decanoate, 0."	5.04	Long-acting oral vs injectable antipsychotic drugs in schizophrenics: a one-year double-blind comparison in multiple episode schizophrenics. ( Kane, J; Klein, DF; Quitkin, F; Ramos-Lorenzi, JR; Rifkin, A, 1978)
"A double-blind, cross-over trial of the effectiveness of piribedil, procyclidine and placebo in the control of parkinsonism induced by fluphenazine decanoate was conducted in sixteen cases of chronic schizophrenia."	5.04	A comparison of piribedil, procyclidine and placebo in the control of phenothiazine-induced parkinsonism. ( Bradley, R; Lamb, P; Mindham, RH, 1977)
"Fifty-seven patients with a diagnosis of schizophrenia were started on either fluphenazine decanoate or flupenthixol decanoate injections in a double-blind trial just prior to discharge into the community."	5.04	Depressive and extrapyramidal symptoms and clinical effects: a trial of fluphenazine versus flupenthixol in maintenance of schizophrenic out-patients. ( Hirsch, SR; Knights, A; Okasha, MS; Salih, MA, 1979)
" A controlled clinical trial has shown oral pimozide to be clinically at least as effective as fluphenazine decanoate in the continuation treatment of schizophrenia."	5.04	Medico-social evaluation of the long-term pharmacotherapy of schizophrenia. Comparative study of fluphenazine and pimozide. ( Shepherd, M, 1979)
"To compare the effects of oral fluphenazine with placebo for the treatment of schizophrenia."	4.98	Fluphenazine (oral) versus placebo for schizophrenia. ( Almerie, MQ; Matar, HE; Sampson, SJ, 2018)
"To measure the outcomes (both beneficial and harmful) of the clinical effectiveness, safety and cost-effectiveness of oral fluphenazine versus atypical antipsychotics for schizophrenia."	4.93	Fluphenazine (oral) versus atypical antipsychotics for schizophrenia. ( Furtado, VA; Li, BG; Sampford, JR; Sampson, S; Xia, J; Zhao, S, 2016)
"To assess the effects of fluphenazine decanoate and enanthate versus oral anti-psychotics and other depot neuroleptic preparations for individuals with schizophrenia in terms of clinical, social and economic outcomes."	4.91	Fluphenazine decanoate (depot) and enanthate for schizophrenia. ( Adams, CE; Asher, R; David, A; Eisenbruch, M; Jayaswal, A; Maayan, N; Quraishi, SN; Rathbone, J, 2015)
"To review the effects of fluphenazine and low-potency antipsychotics for people with schizophrenia."	4.90	Fluphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia. ( Engel, RR; Huhn, M; Leucht, S; Tardy, M, 2014)
"To compare the effects of oral fluphenazine with placebo for the treatment of schizophrenia."	4.89	Fluphenazine (oral) versus placebo for schizophrenia. ( Almerie, MQ; Matar, HE; Sampson, S, 2013)
"To evaluate the effects of oral fluphenazine for schizophrenia in comparison with placebo."	4.84	Oral fluphenazine versus placebo for schizophrenia. ( Almerie, MQ; Matar, HE, 2007)
"We considered all relevant randomised clinical controlled trials focusing on people with schizophrenia comparing fluphenazine decanoate or enanthate with placebo or oral anti-psychotics or other depot preparations."	4.82	Depot fluphenazine decanoate and enanthate for schizophrenia. ( Adams, CE; David, A; Eisenbruch, M; Quraishi, S; Rathbone, J, 2005)
"To compare depot fluphenazine medication to oral fluphenazine for treatment of schizophrenia."	4.80	Depot fluphenazine for schizophrenia. ( Adams, CE; Eisenbruch, M, 2000)
"To compare the effectiveness of different long-acting injectable antipsychotics (LAIs) (aripiprazole, paliperidone, risperidone, and fluphenazine/haloperidol) in patients with schizophrenia in Japan."	4.31	Comparative effectiveness of long-acting injectable antipsychotics in patients with schizophrenia in Japan. ( Akazawa, M; Inada, K; Okada, Y, 2023)
" This study aimed to report a case with bradycardia induced by fluphenazine decanoate administration."	4.12	Fluphenazine decanoate-induced bradycardia: A case report. ( Azizi, M; Elyasi, F; Kamali, M; Zarghami, M, 2022)
"We present a patient with schizophrenia who developed acute and persistent extrapyramidal symptoms requiring tracheostomy and long-term rehabilitation after long-acting injections of fluphenazine decanoate."	3.88	Long-acting formulation leading to severe long-term adverse effects: a case report of fluphenazine and persistent extrapyramidal symptoms. ( Matsunaga, H; Mitsui, Y; Omi, T, 2018)
" For low dose, relapse rates are higher if treatment continues for a second year, if dosage is very low, or if patients are not stable."	3.77	Maintenance medication for schizophrenia: strategies for dose reduction. ( Schooler, NR, 1991)
" This study will present our own experience in the treatment of a pregnant woman suffering from schizophrenia, who was treated with ziprasidone for the duration of her pregnancy."	3.75	Pregnancy and atypical antipsychotics. ( Dadić-Hero, E; Knez, R; Medved, P; Petrić, D; Ruzić, K, 2009)
"This study compares 3 cohorts of patients with schizophrenia before, during, and after initiating treatment with fluphenazine decanoate (FD), haloperidol decanoate (HD), or long-acting injectable risperidone (LAR)."	3.74	Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone. ( Ascher-Svanum, H; Marcus, SC; Olfson, M, 2007)
"To report a case of neuroleptic malignant syndrome (NMS) associated with fluphenazine in a schizophrenic patient and review the literature related to this condition."	3.73	Fluphenazine-induced neuroleptic malignant syndrome in a schizophrenic patient. ( Aruna, AS; Murungi, JH, 2005)
"We describe the case of a 39-year-old patient with schizophrenia who developed worsening of glucose metabolism during treatment with two different atypical antipsychotics, clozapine and quetiapine."	3.73	Importance of oral glucose tolerance test in patient with schizophrenia. ( Aukst-Margetić, B; Badanjak, A; Margetić, B, 2005)
" We report the case of a 36 years old woman suffering from chronic schizophrenia and treated with flufenazine and olanzapine, who presented with series of generalised tonic-clonic seizures as the acute onset of recurrent malignant neuroleptic syndrome."	3.73	Series of seizures as a sign of development of recurrent malignant neuroleptic syndrome - a case report. ( Alvir, D; Kondić, L; Matijević, V; Supe, S, 2006)
"The authors' goal was to explore whether clozapine given as the first antipsychotic treatment favorably affects the course of schizophrenia."	3.72	Clozapine as a first treatment for schizophrenia. ( Alvir, JM; Kane, JM; Lieberman, JA; Robinson, DG; Sheitman, BB; Woerner, MG, 2003)
"One hundred thirty-one acutely ill patients with schizophrenia received 4 weeks of fluphenazine treatment."	3.72	Early prediction of antipsychotic response in schizophrenia. ( Correll, CU; Kane, JM; Kaushik, S; Malhotra, AK; McMeniman, M, 2003)
"We examined the effect of age on psychopharmacological management in a naturalistic study of a group of 165 patients with a clinical diagnosis of schizophrenia or a related psychotic disorder (age range = 21-84 years; subjects > or = 1;45 years n = 86) treated with either haloperidol decanoate or fluphenazine decanoate."	3.71	The effect of age on the pharmacological management of ambulatory patients treated with depot neuroleptic medications for schizophrenia and related psychotic disorders. ( Chengappa, KN; Jeste, DV; Mamo, DC; Reddy, RR; Sweet, RA, 2002)
"On one of our rehabilitation wards, we observed several schizophrenic patients with therapy resistant hallucinations to exhibit complete recovery after being given fluphenazine (2-7."	3.69	[Is there a special indication for fluphenazine in therapy refractory hallucinations?]. ( Bechter, K, 1994)
"Longitudinal assessment and management of the patient resulted in a diagnosis of schizophrenia and treatment with fluphenazine decanoate."	3.69	Intervention and social breakdown in the elderly. ( Little, JD, 1996)
"The regional cerebral glucose metabolic rates of patients with schizophrenia who were and were not receiving neuroleptic drugs and normal control subjects were obtained by positron emission tomography using fludeoxyglucose F 18 as the tracer."	3.69	The brain metabolic patterns of clozapine- and fluphenazine-treated patients with schizophrenia during a continuous performance task. ( Andreason, P; Cohen, RM; Litman, RE; Nordahl, TE; Pickar, D; Semple, WE, 1997)
"Alprazolam, when added under double-blind conditions to a stable neuroleptic regimen in two patients with schizophrenia, resulted in clinically apparent improvement in positive and negative schizophrenic symptoms."	3.67	Combination alprazolam-neuroleptic treatment of the positive and negative symptoms of schizophrenia. ( Breier, A; Doran, AR; Paul, SM; Pickar, D; Tarell, J; Wolkowitz, OM, 1986)
"Neuropeptide Y (a recently discovered brain peptide that is colocalized with norepinephrine within some adrenergic central nervous system neurons) was measured in the cerebrospinal fluid (CSF) from patients with major affective disorder, chronic schizophrenia, and in normal volunteers."	3.67	Cerebrospinal fluid neuropeptide Y in depression and schizophrenia. ( Berrettini, WH; Doran, AR; Kelsoe, J; Pickar, D; Roy, A, 1987)
"We examined the outcome with fluphenazine treatment and ECT in a group of 120 patients according to the incidence of psychopathological symptoms, the patients' status on a variety of sociodemographic and anamnestic variables, and their diagnoses according to 13 systems for diagnosing schizophrenia."	3.67	Characteristics of schizophrenic patients and the outcome of fluphenazine and of electroconvulsive treatments. ( Joseph, L; Landmark, J; Merskey, H, 1987)
"Plasma prolactin and fluphenazine concentrations were measured in a group of 17 patients (9 males, 8 females) with schizophrenia who were receiving chronic treatment with fluphenazine decanoate."	3.67	Plasma prolactin and fluphenazine concentrations in patients receiving fluphenazine decanoate: stability over injection intervals. ( Burrows, GD; Kimber, NM; Marriott, PF; Norman, TR, 1987)
"In a schizophrenic patient, hypothermia was caused by combined treatment with zotepine, biperiden, and fluphenazine, although combined treatment with zotepine and biperiden had caused no side effects."	3.67	Hypothermia caused by antipsychotic drugs in a schizophrenic patient. ( Hashimoto, H; Kamimura, H; Nakajima, T; Nakao, J; Noto, T; Okamoto, K; Sugae, S, 1987)
"A chronic schizophrenic patient received 30 mg fluphenazine hydrochloride (Prolixin) PO and developed priapism."	3.67	Priapism resulting from fluphenazine hydrochloride treatment reversed by diphenhydramine. ( Fishbain, DA, 1985)
"Serum and CSF prolactin (PRL) concentrations were determined during eight weeks of fluphenazine medication in 28 patients with acute symptoms of schizophrenia."	3.67	Serum and cerebrospinal fluid prolactin patterns during neuroleptic treatment in schizophrenic patients. ( Heikkilä, L; Kampman, R; Laru-Sompa, R; Rimón, R, 1985)
"A patient with chronic schizophrenia treated with fluphenazine developed neuroleptic malignant syndrome, characterized by fever, obtundation, rigidity, and tremulousness."	3.66	Neuroleptic malignant syndrome: successful treatment with dantrolene and bromocriptine. ( Adler, S; Coyle, J; Granato, JE; Karim, AH; Krumholz, A; Ringel, A; Stern, BJ, 1983)
"The management of an agitated schizophrenic was complicated by the onset of severe hepatocellular dysfunction concomitant with the administration of fluphenazine, a drug which has rarely been implicated in phenothiazine jaundice."	3.66	Fluphenazine jaundice. Report of a case. ( Snyder, S, 1980)
" Following a reduction in the dose of antipsychotic medications, or their complete discontinuation, mesolimbic dopamine receptor supersensitivity could be reflected in rapid relapse of schizophrenic patients, the development of schizophrenic symptoms in patients with no prior history of schizophrenia, or in the necessity for ever-increasing doses of long-acting depot fluphenazine to maintain a remission."	3.66	Is there a limbic system equivalent of tardive dyskinesia? ( Davis, KL; Rosenberg, GS, 1979)
"Injected intramuscularly, the enanthane and decanoate esters of the phenothiazine fluphenazine are an effective treatment of the disordered behavior and thinking of schizophrenia."	3.65	The long-acting phenothiazines. ( Groves, JE; Mandel, MR, 1975)
"Sixteen patients in whom schizophrenia was initially diagnosed and who were treated with fluphenazine enanthate or decanoate developed severe depression for a short period after the injection."	3.65	Severe depressive mood changes following slow-release intramuscular fluphenazine injection. ( Carney, MW; De Alarcon, R, 1969)
"Treatment with olanzapine moderately decreased, while treatment with fluphenazine significantly increased plasma cortisol levels and muscle rigidity."	2.73	The effects of olanzapine and fluphenazine on plasma cortisol, prolactin and muscle rigidity in schizophrenic patients: a double blind study. ( Jakovljevic, M; Ljubicic, D; Marcinko, D; Mihaljevic-Peles, A; Muck-Seler, D; Mustapic, M; Pivac, N; Relja, M, 2007)
"The effects of 2 family intervention programs (supportive family management [SFM], including monthly support groups for 2 years; or applied family management [AFM], including 1 year of behavioral family therapy plus support groups for 2 years), and 3 different neuroleptic dosage strategies (standard, low, targeted) on social functioning of patients with schizophrenia."	2.70	Family treatment and medication dosage reduction in schizophrenia: effects on patient social functioning, family attitudes, and burden. ( Bellack, AS; Glick, ID; Keith, SJ; Mueser, KT; Schooler, NR; Sengupta, A; Xie, H, 2001)
"Since schizophrenia is a common condition and treatment is usually long-term, this has important financial implications."	2.69	Generic substitution--comparing the clinical efficacy of a generic substitute for fluphenazine decanoate with the original product. ( Joubert, G; Stevens, M; van der Merwe, H; Verster, GC, 1998)
"Oral fluphenazine was given in fixed, randomized, double-blind doses (10, 20, or 30 mg/day) for 4 weeks to 72 inpatients with acute schizophrenic exacerbations."	2.68	Fluphenazine plasma levels, dosage, efficacy, and side effects. ( Cooper, TB; Levinson, DF; Lo, ES; Simpson, GM; Singh, H; Stephanos, MJ; Yadalam, K, 1995)
" These patients were treated primarily with fluphenazine decanoate, and five distinct dosing strategies with this agent were identified retrospectively."	2.68	Transition from acute to maintenance treatment: prediction of stabilization. ( Glick, ID; Hargreaves, WA; Keith, SJ; Schooler, NR; Severe, JB; Weiden, P, 1996)
" Dosage data from the first 208 successfully-stabilized TSS subjects were examined."	2.67	Stabilization and depot neuroleptic dosages. ( Lee, JH; Schooler, NR; Schulz, SC; Severe, JB; Weiden, P, 1993)
"This study uses the highly sensitive method of gas chromatography/mass spectrometry to compare the basic steady-state pharmacokinetic parameters of two fluphenazine decanoate formulations."	2.67	The determination of the steady-state pharmacokinetic profile of fluphenazine decanoate by gas chromatography/mass spectrometry detection. ( Brown, WA; Friedhoff, LT; Glazer, WM; Marder, SR, 1992)
"During long-term treatment of schizophrenia with antipsychotic medication, side effects such as weight gain and tardive dyskinesia may develop, while other extrapyramidal side effects may continue."	2.67	Side effects during long-term treatment with depot antipsychotic medication. ( Cookson, JC, 1991)
" These findings suggest that the measurement of fluphenazine plasma levels may be helpful in decision-making about the dosage of FD."	2.67	Fluphenazine plasma levels and clinical response. ( Aravagiri, M; Hawes, EM; Hubbard, JW; Marder, SR; McKay, G; Midha, KK; Mintz, J; Van Putten, T, 1990)
"Eighty-six patients with acute psychotic exacerbations were treated with fixed dosage regimens of oral fluphenazine up to 10-30 mg/day in randomized, double-blind studies."	2.67	Acute dystonia during fixed-dose neuroleptic treatment. ( Friedman, E; Levinson, DF; Lo, ES; Simpson, GM; Singh, H, 1990)
" Results suggested an absorption half-life of 4 weeks, although, in three cases steady state was only achieved after 11 monthly injections."	2.67	Pharmacokinetics of haloperidol and fluphenazine decanoates in chronic schizophrenia. ( McCreadie, RG; Whitehead, A; Wiles, DH, 1990)
" The dosage equivalency of haloperidol decanoate (1."	2.66	A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia. ( Annable, L; Campbell, W; Chouinard, G, 1989)
" When plasma levels from both dosage groups were combined, FLU at 12 weeks correlated significantly with factor scores for akinesia (r = 0."	2.66	Fluphenazine plasma levels in patients receiving low and conventional doses of fluphenazine decanoate. ( Hawes, EM; Hubbard, JW; Marder, SR; May, PR; McKay, G; Midha, KK; Mintz, J; Van Putten, T, 1986)
"Issues regarding the side effects of antipsychotic medication and the possible contribution of the environment to dose requirements led to a two-year controlled dosage study of maintenance antipsychotic medication and familial environment among recently discharged schizophrenic patients."	2.66	Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Results of a two-year controlled study. ( Bartone, P; Carter, M; Cather, R; Cooley, SJ; DiBarry, AL; Hogarty, GE; Madonia, MJ; McEvoy, JP; Munetz, M; Ulrich, RF, 1988)
" There was no significant difference in survival when the clinician was permitted to make a dosage adjustment up to 10 mg in the low-dose group and 50 mg in the higher-dose group when the patient demonstrated evidence of a symptomatic exacerbation."	2.66	Low- and conventional-dose maintenance therapy with fluphenazine decanoate. Two-year outcome. ( Lebell, M; Marder, SR; May, PR; McKenzie, J; Mintz, J; Van Putten, T, 1987)
" The evidence available from prospective controlled trials suggests that substantial dosage reduction is feasible for a subgroup of outpatient schizophrenics and that the incidence of abnormal involuntary movements might be reduced by such a strategy."	2.65	Low dose medication strategies in the maintenance treatment of schizophrenia. ( Kane, JM, 1983)
" Maximum concentrations appeared at 1 week after administration of cis(Z)-clopenthixol decanoate, whereas the highest concentrations after fluphenazine decanoate were seen at the end of the 3-week dosage interval."	2.65	Blood and plasma kinetics of cis(Z)-clopenthixol and fluphenazine in psychiatric patients after intramuscular injection of their decanoic esters. ( Ba, B; Berda, C; D'Agostino, N; Dufour, H; Durand, A; Hou, N; Jørgensen, A; Viala, A, 1984)
" High Dosage resulted in PRL levels significantly greater than found during Low Dose treatment in 9 of 11 patients."	2.65	Plasma fluphenazine and prolactin levels in schizophrenic patients during treatment with low and high doses of fluphenazine enanthate. ( Dencker, SJ; Franklin, M; Johansson, R; Lundin, L; Malm, U; Wiles, D, 1980)
"Relapse was often characterized by a return of the dame symptoms as the patient had during his first schizophrenic attack."	2.65	A depot neuroleptic withdrawal study. A controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients. ( Wistedt, B, 1981)
" A factorial covariance-analysis showed that differences in the initial hostility-syndrome and catatonic-syndrome scores are predictors for a syndrom-relevant differential dosage per group."	2.65	[Drug-response differences of high and standard dosage of fluphenazine-decanoate in relation to schizophrenic symptoms (author's transl)]. ( Fararuni, M; Heinrich, K; Lehmann, E; Quadbeck, H; Tegeler, J, 1980)
" The dosage of drugs was varied according to clinical indications."	2.65	A comparative trial of the decanoates of flupenthixol and fluphenazine. ( Card, IR; Hamilton, M; Mahmoud, MR; Wallis, GG, 1979)
" The results suggest that lower doses of fluphenazine decanoate than those usually used may be effective in preventing psychotic relapse while keeping total cumulative dosage to a minimum."	2.65	Low dose fluphenazine decanoate in maintenance treatment of schizophrenia. ( Kane, JM; Klein, DF; Nayak, D; Quitkin, F; Ramos-Lorenzi, JR; Rifkin, A; Sachar, EJ; Saraf, K, 1979)
" The 44 patients in this study were randomly assigned to the psychotherapy condition and to either a high or low dosage of phenothiazines."	2.65	Therapist ratings of achievement of objectives in psychotherapy with acute schizophrenics. ( Goldstein, MJ; King, CE, 1979)
" The most often applied dosage was 100 mg pipothiazine palmitate and 25 or 37."	2.64	[Comparison of the effects of pipothiazine palmitate and fluphenazine decanoate. Results of a multicenter double-blind trial]. ( Angst, J; Dick, P; Fleischhauer, HJ; Gmür, M; Gruber, G; Heimann, H; Woggon, B, 1977)
" Improvement was recorded in a double blind study of 18 patients treated with maximum tolerated dosage (mean 18."	2.64	Tardive dyskinesia treated with pimozide. ( Calne, DB; Claveria, LE; Haskayne, L; Lodge-Patch, IC; Pallis, CA; Petrie, A; Teychenne, PF, 1975)
"/day) versus fixed standard dosage (20 mg."	2.64	High vs standard dosage fluphenazine HCL in acute schizophrenia. ( Donlon, PT; Meadow, A; Tupin, JP; Wahba, M, 1978)
"Fluphenazine decanoate treatment causes significantly more depressive syndromes than does placebo."	2.64	[Pharmacogenic depressive syndromes in the course of schizophrenic psychoses (author's transl)]. ( Kind, J; Müller, P; Steuber, H, 1978)
"Benztropine was prescribed only if needed and was administered to 65% of patients."	2.64	The initiation of long-term pharmacotherapy in schizophrenia: dosage and side effect comparisons between oral and depot fluphenazine. ( Levine, J; Schooler, NR, 1976)
"Relapse was accompanied by a resurgence of specifically schizophrenic symptoms and by an increase in abnormalities described by the relatives."	2.64	Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial. Report to the Medical Research Council Committee on Clinical Trials in Psychiatry. ( Gaind, R; Hirsch, SR; Rohde, PD; Stevens, BC; Wing, JK, 1973)
"Fluphenazine is an inexpensive and widely accessible antipsychotic drug that has been available to treat people with schizophrenia for five decades."	2.49	Fluphenazine (oral) versus placebo for schizophrenia. ( Almerie, MQ; Matar, HE; Sampson, S, 2013)
" To deal with pharmacokinetic aspects two main topics are discussed in this paper: (A) the interindividual differences in bioavailability and metabolism and (B) the plasma level-clinical response relationship."	2.38	A multidimensional (pharmacokinetic and clinical-biological) approach to neuroleptic response in schizophrenia. With particular reference to drug resistance. ( Altamura, AC, 1993)
" In addition, the clinician should consider the dosage schedule of each medication and balance this against the probability of extrapyramidal side effects and noncompliance."	2.38	Dose response of prophylactic antipsychotics. ( Brauzer, B; Casey, DE; Davis, JM; Gierl, B; Hassan, M; Kane, JM; Marder, SR; Schooler, N, 1993)
"The comorbidity of schizophrenia and idiopathic Parkinson's disease (IPD) is illustrated by a case description of a schizophrenic patient who develops motor symptoms finally diagnosed and treated as comorbid IPD."	1.40	Clinical aspects of comorbid schizophrenia and idiopathic Parkinson's disease. ( de Jong, MH; Van Gool, AR; Zemel, D, 2014)
"Co-occurring substance use disorders (SUD), including alcohol, are common in schizophrenia (SZ) and are associated with poor outcome."	1.40	Schizophrenia and co-occurring substance use disorder: reward, olfaction and clozapine. ( Gibson, LE; Green, AI; Mesholam-Gately, RI; Seidman, LJ, 2014)
"9% of the total antipsychotic dosage on average."	1.39	Ten year outcomes of outpatients with schizophrenia on conventional depot antipsychotics: a systematic chart review. ( Den, R; Mimura, M; Sakurai, H; Suzuki, T; Tsutsumi, C; Uchida, H; Uchida, T, 2013)
"Schizophrenia is thought to be the psychiatric diagnosis the most frequently associated with TD."	1.39	[Tardive dyskinesia induced by classical antipsychotic drugs: a Tunisian sample of schizophrenics]. ( Bellaaj, R; Bouguerra, C; Gallali, S; Mehdi, F; Oumaya, A; Sejil, I, 2013)
"Schizophrenia Care and Assessment Program, a large, prospective study of treatment for schizophrenia conducted July 1997 through September 2003."	1.34	Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. ( Ascher-Svanum, H; Faries, D; Marder, SR; Montgomery, W; Shi, L; Zhu, B, 2007)
"The novel antipsychotic medications offer a more favorable extrapyramidal side effect profile than conventional agents."	1.31	Sexual side effects of novel antipsychotic medications. ( Marder, SR; Pierre, JM; Saunders, CS; Wirshing, DA; Wirshing, WC, 2002)
"Treatment of schizophrenia is often complicated by substance abuse."	1.30	Alcohol dependence and hospitalization in schizophrenia. ( Arana, GW; Gerding, LB; Labbate, LA; Measom, MO; Santos, AB, 1999)
" The aim of the study was to find out whether age at onset of schizophrenia is related to the dosage of typical neuroleptics in outpatients."	1.30	Age at onset of schizophrenia and neuroleptic dosage. ( Dernovsek, MZ; Tavcar, R, 1999)
"The neuroleptic malignant syndrome is an exceedingly rare but potentially fatal condition characterized by parkinsonian type rigidity, rise of temperature and altered consciousness."	1.28	An unusual presentation of neuroleptic malignant syndrome. ( Basu, J, 1991)
"Fluphenazine was significantly effective in treating symptoms such as emotional withdrawal, blunted affect, suspiciousness, thought disturbances, but not hallucinations."	1.28	Clinical and toxicological profile of fluphenazine decanoate in elderly chronic schizophrenia. ( Altamura, AC; Girardi, T; Mauri, MC; Panetta, B, 1990)
" The authors examined the possibilities of a pharmacokinetic effect of alprazolam on neuroleptic plasma levels and of a clinical effect of alprazolam."	1.28	Neuroleptic augmentation with alprazolam: clinical effects and pharmacokinetic correlates. ( Angrist, B; Cooper, T; Douyon, R; Peselow, E; Rotrosen, J, 1989)
"A study of patterns of neuroleptic dosage for 206 schizophrenic inpatients showed significant differences over time and among three centers--a general hospital psychiatric unit, a community mental health center, and a state hospital."	1.28	Changing patterns of neuroleptic dosage over a decade. ( Myerson, A; Reardon, GT; Rifkin, A; Schwartz, A; Siris, SG, 1989)
"The authors studied high-potency versus low-potency neuroleptic dosing practices for 110 Boston-area psychiatric inpatients and compared the findings with the dosing practices reported in surveys of nearly 16,000 Veterans Administration patients."	1.27	Dissimilar dosing with high-potency and low-potency neuroleptics. ( Baldessarini, RJ; Cotton, P; Katz, B, 1984)
"Oral haloperidol was given before and after each drug."	1.27	Within-individual variation in steady state plasma levels of different neuroleptics and prolactin. ( Hansen, V; Jorgensen, A; Mackie, M; McCreadie, RG; Menzies, C; Wiles, DH, 1984)
" Moreover pharmacokinetic data increasingly have been clinically applied."	1.27	Chemotherapy with neuroleptics. Clinical and pharmacokinetic aspects with a particular view to depot preparations. ( Knudsen, P, 1985)
"Seventeen outpatients were treated with depot neuroleptics, zuclopenthixol decanoate in Viscoleo or fluphenazine decanoate in sesame oil, with dosage intervals of 3 weeks."	1.27	Comparative study of the pharmacokinetics of zuclopenthixol decanoate and fluphenazine decanoate. ( Ba, B; Durand, A; Gouezo, F; Hou, N; Jørgensen, A; Viala, A, 1988)
"Haloperidol was given to 8 patients for 10 days (group A: 0."	1.27	Effects of neuroleptic treatments on peripheral opioid secretion. ( Bellodi, L; Brambilla, F; Brancato, V; Facchinetti, F; Genazzani, AR; Petraglia, F; Smeraldi, E, 1987)
"Obesity is associated with increased morbidity and may reduce compliance, leading to a return of psychotic symptoms."	1.27	Prevalence of obesity in patients receiving depot antipsychotics. ( Goodall, E; Silverstone, T; Smith, G, 1988)
" There were statistically significant tendencies for mean plasma fluphenazine levels to rise and mean plasma sulfoxide levels to fall over the 6-month period of study among patients on the high dose, consistent with our previously reported observation that it takes 3-6 months to establish a steady state of fluphenazine with this dosage regimen."	1.27	The sulfoxidation of fluphenazine in schizophrenic patients maintained on fluphenazine decanoate. ( Hawes, EM; Hubbard, JW; Marder, SR; May, PR; McKay, G; Midha, KK; Van Putten, T, 1987)
"The fluphenazine plasma levels were rather constant in the individual patients during this period."	1.27	Pharmacokinetic and pharmacodynamic studies on high doses of fluphenazine. ( Dencker, SJ; Johansson, R; Malm, U, 1988)
" Based on the study of plasma levels achieved with FPZ-D injection and oral FPZ-H (fluphenazine HC1) in 6 patients, the dosage requirement of FPZ-D appeared to be difficult to predict from the oral dosage of FPZ-H in the same patient."	1.27	Plasma levels of fluphenazine during fluphenazine decanoate treatment in schizophrenia. ( Casper, RC; Chang, SS; Davis, JM; Dysken, MW; Janicak, PG; Javaid, JI, 1985)
" To gather relevant data on pharmacokinetic characteristics of depot fluphenazines, the authors measured plasma levels of neuroleptic activity in 76 clinic patients on stable dosage regimens of fluphenazine decanoate or fluphenazine enanthate."	1.27	Plasma levels of neuroleptic in patients receiving depot fluphenazine. ( Chouinard, G; Cohen, BM; Jones, B; Sommer, BR; Waternaux, C, 1985)
"In 14 schizophrenic patients, prolactin levels are studied in relation to dosage of depot fluphenazine and gender of patient."	1.27	Depot fluphenazine and plasma prolactin. ( Gift, T; Plum, K; Price, M, 1985)
"Thioridazine levels were substantially higher than those of other neuroleptics."	1.26	Neuroleptic serum levels measured by radioreceptor assay and clinical response in schizophrenic patients. ( Creese, I; DePaulo, JR; Slavney, PR; Snyder, SH; Tune, LE, 1981)
"The determinants of relapse have been elusive."	1.26	Low serum neuroleptic levels predict relapse in schizophrenic patients. ( Brown, WA; Chisholm, E; Laughren, T; Williams, BW, 1982)
"This high rate of relapse is viewed as indicating the need for continued medication in most chronic schizophrenic patients."	1.26	Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients. ( Aderounmu, AF; Odejide, OA, 1982)
"281 newly admitted female schizophrenic patients were treated with high dosage fluphenazine decanoate intramuscularly, starting with 250 mg per injection together with antiparkinsonian and antidepressant drugs."	1.26	Follow-up study of 281 schizophrenic patients treated with high dosage fluphenazine decanoate. ( Nagy, C; Steiner, S, 1981)
" The clinical effectivity came up to the usual therapy with normal high dosage after 28 days therapy, a somewhat more rapid deliverance of symptoms during the first days remained impressive."	1.26	High dosage treatment with fluphenazine intravenously followed by depot injections in acute schizophrenia. ( Fleischhauer, J, 1980)
"These episodes are differentiated from nocturnal wanderings and epileptic attacks during sleep; they occurred within two to three hours after sleep onset and were characterized by the patients appearing confused and walking about in a quiet, detached and clumsy manner."	1.26	Somnambulistic-like episodes secondary to combined lithium-neuroleptic treatment. ( Charney, DS; Kales, A; Nelson, JC; Soldatos, CR, 1979)
" An individualized approach to the dosage of Fluphenazine decanoate must be practiced in conjunction with, and taking into account the time spent in treatment and the sex and age variables reported."	1.26	Drug monitoring at an Australia depot phenothiazine clinic. ( Hiep, A; Marriott, P, 1978)
" The data suggest that neither prophylactic nor long-term use of antiparkinsonian agents is necessary for most patients receiving fluphenazine decanoate."	1.26	Antiparkinsonian agents and fluphenazine decanoate. ( Idzorek, S, 1976)
" (2) It allows a diminution of the maintenance dosage and thereby reduces the occurrence of side-effects and furthermore the danger of the chemo-toxic damaging of a series of inner organs and systems."	1.25	[Depot fluphenazine as a means of stabilizing remission in cases of schizophrenia]. ( Vovin, RIa; Vovina, EN, 1975)
" In view of current interest in depot psychopharmaceuticals, they recommend that careful attention be given to dosage and administration schedules and to the possibility of delayed pseudoparkinsonian symptoms."	1.25	Delayed severe extrapyramidal disturbance following frequent depot phenothiazine administration. ( Warner, AM; Wyman, SM, 1975)

Research

Studies (836)

Authors

Clinical Trials (13)

Trial Overview

Trial Outcomes

Number Who Discontinued Medication Within First 6 Study Months

Change in MATRICS Consensus Cognitive Battery (MCCB)

Timeframe	Studies, this research(%)	All Research%
pre-1990	640 (76.56)	18.7374
1990's	116 (13.88)	18.2507
2000's	49 (5.86)	29.6817
2010's	24 (2.87)	24.3611
2020's	7 (0.84)	2.80

Authors	Studies
Nudelman, A	1
Gil-Ad, I	1
Shpaisman, N	1
Terasenko, I	1
Ron, H	1
Savitsky, K	1
Geffen, Y	1
Weizman, A	3
Rephaeli, A	1
Socco, S	1
Jhawar, A	1
Riddle, MA	1
Kamali, M	1
Zarghami, M	1
Azizi, M	1
Elyasi, F	1
Misawa, F	1
Fujii, Y	1
Takeuchi, H	1
Okada, Y	1
Inada, K	1
Akazawa, M	1
López-Herrero, F	1
Contreras-Díaz, M	1
Sánchez-Vicente, JL	1
Crosta, CM	1
Hernandez, K	1
Bhattiprolu, AK	1
Fu, AY	1
Moore, JC	1
Clarke, SG	1
Dudzinski, NR	1
Brzustowicz, LM	1
Paradiso, KG	1
Firestein, BL	1
Ostuzzi, G	1
Bertolini, F	1
Del Giovane, C	1
Tedeschi, F	1
Bovo, C	1
Gastaldon, C	1
Nosé, M	1
Ogheri, F	1
Papola, D	1
Purgato, M	1
Turrini, G	1
Correll, CU	2
Barbui, C	1
Omi, T	1
Mitsui, Y	1
Matsunaga, H	1
Zanker, J	1
Ferraro, A	1
Samara, MT	1
Klupp, E	1
Helfer, B	1
Rothe, PH	1
Schneider-Thoma, J	1
Leucht, S	2
Matar, HE	4
Almerie, MQ	4
Sampson, SJ	1
de Jong, MH	1
Zemel, D	1
Van Gool, AR	1
Kirk Morton, N	1
Zubek, D	1
Stanković, Z	2
Ille, T	2
Uchida, T	1
Suzuki, T	1
Sakurai, H	1
Tsutsumi, C	1
Den, R	1
Mimura, M	1
Uchida, H	1
Sampson, S	3
Birkeland, SF	1
Mesholam-Gately, RI	1
Gibson, LE	1
Seidman, LJ	2
Green, AI	2
Tardy, M	1
Huhn, M	1
Engel, RR	1
Maayan, N	1
Quraishi, SN	1
David, A	2
Jayaswal, A	1
Eisenbruch, M	3
Rathbone, J	2
Asher, R	1
Adams, CE	3
Sampford, JR	1
Li, BG	1
Zhao, S	1
Xia, J	1
Furtado, VA	1
Smerud, PE	1
Rosenfarb, IS	2
Byne, W	1
Tatusov, A	1
Yiannoulos, G	1
Vong, GS	1
Marcus, S	1
Rajarethinam, R	2
Dziuba, J	1
Manji, S	1
Pizzuti, A	1
Lachover, L	1
Keshavan, M	1
Ruzić, K	1
Dadić-Hero, E	1
Knez, R	1
Medved, P	1
Petrić, D	1
Citrome, L	1
Jaffe, A	1
Levine, J	6
John, SM	1
Venkatesan, S	1
Tharyan, A	1
Bhattacharji, S	1
Goodwin, DG	1
Strobl, JS	1
Lindsay, DS	1
Bola, J	1
Kao, D	1
Soydan, H	2
Popović, I	1
Ravanić, D	1
Popović, V	1
Vladejić, S	1
Stanojević, A	1
Stojanović, M	1
Bola, JR	1
Kao, DT	1
Kucharska-Pietura, K	1
Tylec, A	1
Czernikiewicz, A	1
Mortimer, A	1
Covell, NH	1
McEvoy, JP	5
Schooler, NR	19
Stroup, TS	1
Jackson, CT	1
Rojas, IA	1
Essock, SM	1
Sejil, I	1
Oumaya, A	1
Bouguerra, C	1
Mehdi, F	1
Bellaaj, R	1
Gallali, S	1
Maloney, DM	1
Mamo, DC	1
Sweet, RA	1
Chengappa, KN	1
Reddy, RR	1
Jeste, DV	1
Bilici, M	1
Cakirbay, H	1
Guler, M	1
Tosun, M	1
Ulgen, M	1
Tan, U	1
Gilani, S	1
Tancer, M	1
DeQuardo, J	1
Conley, RR	4
Kelly, DL	4
Love, RC	2
McMahon, RP	1
Woerner, MG	4
Robinson, DG	1
Alvir, JM	4
Sheitman, BB	1
Lieberman, JA	6
Kane, JM	10
HOWELL, RJ	1
BROWN, HM	1
BEAGHLER, HE	1
REZNIKOFF, L	1
SAINZ, A	1
KRUSE, W	2
MUKASA, H	1
ICHIHARA, T	1
MATSUOKA, S	1
AKIYAMA, K	2
ALEXANDER, HG	1
SHAWVER, JR	1
SCARBOROUGH, JS	1
FRANK, TV	1
STRANG, WC	1
FRENCH, R	1
STRATAS, NE	1
GROSS, H	1
KALTENBAECK, E	1
BARDIS, C	1
GAYRAL, L	4
STERN, H	1
ROBERT, MP	1
da SILVA, A	1
BARROS, JJ	1
MEIRELLES, P	1
OLIVEIRA, JD	1
YAMAUCHI, I	1
DELAY, J	1
DENIKER, P	1
LEYRIE, J	1
CONTE, C	1
DETRE, TP	1
FELDMAN, RG	1
ROSNER, B	1
FERRITER, C	1
FLEGEL, H	1
MADALENA, JC	2
SHAW, CR	1
LOCKETT, HJ	1
LUCAS, AR	1
LAMONTAGNE, CH	1
GRIMM, F	1
CHILDERS, RT	1
INVERNIZZI, G	2
HORDERN, A	1
KING, A	1
HOLT, NF	1
COLLINS, HJ	1
TOUSSAINT, J	1
POLLACK, SL	1
TOURLENTES, TT	1
ZOCCHI, AF	1
ECKMANN, F	1
IMMICH, H	1
ZIPORYN, M	1
STONER, HE	1
MORI, A	1
YABUKI, Y	1
KLERMAN, GL	3
DAVIDSON, EM	1
KAYCE, MM	1
RAVARIS, CL	2
WEAVER, LA	2
BROOKS, GW	2
ULETT, GA	1
BOWERS, CA	1
HEUSLER, AF	1
QUICK, R	1
WORD, T	1
WORD, V	1
LERNER, J	1
SIMPSON, GM	12
AMIN, M	1
KUNZ, E	1
MCCAFFERTY, FV	1
GANTZ, RS	1
BIRKETT, DP	1
MARGOLIS, LH	1
GOBLE, JL	1
BARSA, JA	1
SAUNDERS, JC	1
KINROSS-WRIGHT, J	1
ROWELL, RC	1
Malhotra, AK	1
Kaushik, S	1
McMeniman, M	1
Dossenbach, MR	1
Folnegovic-Smalc, V	1
Hotujac, L	2
Uglesic, B	1
Tollefson, GD	1
Grundy, SL	1
Friedel, P	1
Jakovljevic, MM	1
Bellack, AS	3
Aziz, N	1
Kratz, KM	1
Sayers, S	1
Buckley, PF	1
Goldstein, JM	1
Emsley, RA	1
Stryjer, R	1
Grupper, D	1
Strous, R	1
Poyurovsky, M	1
Turner, M	1
Eerdekens, E	1
Jacko, M	1
Eerdekens, M	1
Putzhammer, A	2
Perfahl, M	2
Pfeiff, L	2
Broll, K	1
Hess, L	1
Ibach, B	2
Quraishi, S	1
Aruna, AS	1
Murungi, JH	1
Johann, M	1
Zitzelsberger, U	1
Hajak, G	1
Margetić, B	2
Aukst-Margetić, B	1
Badanjak, A	1
Supe, S	1
Matijević, V	1
Kondić, L	1
Alvir, D	1
Baptista, T	1
Martinez, M	1
Lacruz, A	1
Arellano, A	1
Mendoza, S	1
Beaulieu, S	1
Hernández, L	1
Contreras, Q	1
Galeazzi, T	1
Vargas, D	1
Jakovljevic, M	2
Pivac, N	1
Mihaljevic-Peles, A	2
Mustapic, M	1
Relja, M	1
Ljubicic, D	1
Marcinko, D	1
Muck-Seler, D	1
Glazer, WM	5
Shi, L	2
Ascher-Svanum, H	3
Zhu, B	2
Faries, D	2
Montgomery, W	2
Marder, SR	29
Olfson, M	1
Marcus, SC	1
Aukst Margetić, B	1
Small, JG	2
Kellams, J	1
Schlagenhauf, F	1
Juckel, G	1
Koslowski, M	1
Kahnt, T	1
Knutson, B	1
Dembler, T	1
Kienast, T	1
Gallinat, J	1
Wrase, J	1
Heinz, A	1
Britvić, D	1
Vuković, O	1
Glick, ID	5
Siris, SG	14
Davis, JM	8
McIlrath, WA	1
Malster, BJ	1
Lowther, J	2
Goldberg, SC	6
Mattsson, N	2
Cole, JO	4
Tune, LE	2
Creese, I	3
Coyle, JT	1
Pearlson, G	1
Snyder, SH	3
Kabes, J	1
Balon, R	2
Hanzlícek, L	1
Skovajsová, M	1
Kozáková, H	1
Hartmann, W	2
Kind, J	3
Meyer, JE	1
Müller, P	5
Steuber, H	3
Dysken, MW	3
Chang, SS	3
Schaffer, C	2
Casper, RC	2
Javaid, JI	3
DePaulo, JR	1
Slavney, PR	1
Nurnberg, HG	2
Greenwald, B	1
DeLisi, LE	1
Wise, CD	1
Bridge, TP	1
Rosenblatt, JE	1
Wagner, RL	1
Morihisa, J	1
Karson, C	1
Potkin, SG	2
Wyatt, RJ	1
Waddington, JL	1
Gamble, SJ	1
Cooper, SF	1
Lapierre, YD	5
Schneider, SJ	1
Kirby, EJ	1
Itil, TM	6
Chouinard, G	9
Annable, L	6
Ross-Chouinard, A	3
Braddock, LE	1
Blake, IM	1
Kabesh, Ia	1
Papezhova, G	1
Coufal, J	1
Novotný, M	1
Mandel, MR	4
Severe, JB	6
Gelenberg, AJ	3
Mieske, M	2
Brown, WA	6
Laughren, T	1
Chisholm, E	1
Williams, BW	1
Baron, M	3
Gruen, R	3
Levitt, M	3
Kane, J	10
van der Kolk, BA	1
Goldberg, HL	2
Walker, CA	1
Johnson, DA	12
Pasterski, G	1
Ludlow, JM	1
Street, K	1
Taylor, RD	1
Hogan, TP	1
Awad, AG	1
von Frenckell, R	1
Hofmann, G	1
Escobar, JI	1
Barron, A	1
Kiriakos, R	1
Goodnick, PJ	1
Tong, C	1
Duncavage, MB	1
Meltzer, HY	4
Oyewumi, LK	1
Gray, R	1
Batth, S	1
Gelfand, R	1
Dencker, SJ	8
Hogarty, GE	6
Leff, J	2
Kuipers, L	1
Berkowitz, R	1
Eberlein-Fries, R	1
Sturgeon, D	1
Baldessarini, RJ	2
Katz, B	1
Cotton, P	1
Ostow, M	1
McCreadie, RG	5
Mackie, M	3
Wiles, DH	7
Jorgensen, A	1
Hansen, V	1
Menzies, C	1
Viala, A	2
Hou, N	2
Ba, B	2
Durand, A	2
Dufour, H	1
D'Agostino, N	1
Berda, C	1
Jørgensen, A	3
Asarnow, RF	2
Van Putten, T	21
Rifkin, A	18
Quitkin, F	13
Nayak, D	4
Ramos-Lorenzi, J	2
Woerner, M	3
Reardon, G	2
Sarantakos, S	1
Schiebel, D	1
Wistedt, B	5
Ranta, J	1
McKane, JP	2
Watt, DC	4
Katz, K	1
Shepherd, M	4
Barnes, TR	6
Milavic, G	1
Curson, DA	5
Platt, SD	5
Campbell, W	2
Boisvert, D	2
Bradwejn, J	2
Mavroidis, ML	1
Kanter, DR	1
Hirschowitz, J	2
Garver, DL	3
Mintz, J	15
McKenzie, J	4
Lebell, M	5
Faltico, G	1
May, PR	6

Trial	Phase	Enrollment	Study Type	Start Date	Status
Effectiveness of Switching Antipsychotic Medications[NCT00044655]	Phase 4	219 participants (Actual)	Interventional	2001-07-31	Completed
A Multicenter Ascending Dose, Double Blind, Placebo-controlled Study of NAP (AL-108) in Chronic Schizophrenia[NCT00505765]	Phase 2	63 participants (Actual)	Interventional	2007-07-31	Completed
A Survey of Sexual Function in Schizophrenic Patients[NCT01835522]		0 participants (Actual)	Observational	2009-07-31	Withdrawn
Multimodal Neural Investigation of Reward Processing in Mental Illness[NCT03068793]		80 participants (Actual)	Observational	2013-10-01	Completed
Alterations in mRNA and Protein Expression in Human Peripheral Mononuclear Blood Cells (PMC) of Schizophrenia Patients Treated With Fluvoxamine Augmentation of Antipsychotics: Relationship to Clinical Symptoms and Cognitive Function[NCT00645580]		15 participants (Anticipated)	Interventional	2008-04-30	Active, not recruiting
Pharmacological Approach to Improve the Outcome of Social Cognition Training[NCT01517360]	Phase 1	27 participants (Actual)	Interventional	2012-01-31	Completed
MK-0777 for the Treatment of Cognitive Impairments in Patients With Schizophrenia[NCT00505076]	Phase 2	63 participants (Actual)	Interventional	2007-07-31	Completed
ExPRESS:2 (Experiences of Psychosis Relapse: Early Subjective Signs) Longitudinal Feasibility Study[NCT03558529]		27 participants (Actual)	Observational	2015-05-01	Completed
MAintain the Efficacy and Safety in Treatment of Schizophrenia After Switching to Long-acTing Injectable aRipiprazole From Oral Atypical Antipsychotics[NCT03376763]	Phase 4	201 participants (Actual)	Interventional	2017-11-21	Completed
A Double-Blind, Placebo-Controlled Trial of Rosiglitazone for Clozapine Induced Glucose Metabolism Impairment: Bergman's Minimal Model Analysis[NCT00337350]	Phase 4	20 participants (Actual)	Interventional	2003-09-30	Completed
An Open Label Trial of Ziprasidone as an Adjuvant for Clozapine- or Olanzapine-Associated Diabetes Mellitus or Impaired Fasting Glucose in Chronic Schizophrenia[NCT00351000]	Phase 4	24 participants (Actual)	Interventional	2005-01-31	Completed
Phase IV Study of Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia[NCT00595504]	Phase 4	25 participants (Actual)	Interventional	2008-01-31	Completed
Study of add-on Ramelteon Therapy on Sleep and Circadian Rhythm Disruption in Patients With Schizophrenia[NCT03075657]	Phase 4	120 participants (Actual)	Interventional	2017-05-01	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Intervention	participants (Number)
Stay	11
Switch	23

The MATRICS Consensus Cognitive Battery (MCCB) measures functioning across various cognitive domains and is comprised of ten tests that assess seven cognitive domains (speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition) Its measurements are based on timed paper-and-pencil, computerized, and orally-administered tests, as well as spatial tests using geometric cubes. MCCB composite T scores are between 40 and 60 (normal range) and < 40 (below normal range). (NCT00505765)
Timeframe: Baseline, 12 weeks

Change in MATRICS Consensus Cognitive Battery Composite Score Change

Intervention	units on a scale (Mean)
AL-108, 30 mg/Day	3.9
AL-108, 5 mg/Day	4.6
Placebo	3.2

Change in SCoRS Interviewer Global Rating

Intervention	units on a scale (Mean)
AL-108, 30 mg/Day	1.3
AL-108, 5 mg/Day	2.3
Placebo	-0.2

Schizophrenia Cognition Rating Scale (SCoRS) assessed functional capacity by completing a 20-question rating scale via interviews with the subject and an informant, focusing on cognitive impairment and its impact on daily functioning. After the interview, the interviewer rated subject's overall difficulty on a Global Scale of 1-10. Higher scores indicate greater cognitive impairment. (NCT00505765)
Timeframe: Baseline, 12 weeks

Change in SCoRS Interviewer Global Rating

Intervention	units on a scale (Mean)
AL-108, 30 mg/Day	-0.4
AL-108, 5 mg/Day	-1.2
Placebo	-0.3

Change in UCSD Performance-Based Skills Assessment (UPSA) Summary Scores

Intervention	units on a scale (Mean)
AL-108, 30 mg/Day	0.1
AL-108, 5 mg/Day	-0.6
Placebo	-0.1

UPSA includes 5 skill areas (subscales) with scores that each range from 0-20. The UPSA yields an overall total score which is the sum of the five subscales and ranges from 0-100. Higher scores are associated with more independent living. (NCT00505765)
Timeframe: Baseline, 12 weeks

Change in UCSD Performance-Based Skills Assessment (UPSA) Summary Scores

Intervention	units on a scale (Mean)
AL-108, 30 mg/Day	4.9
AL-108, 5 mg/Day	8.9
Placebo	0.3

Composite MATRICS Consensus Cognitive Battery Score

Intervention	units on a scale (Mean)
AL-108, 30 mg/Day	2.9
AL-108, 5 mg/Day	7.2
Placebo	-0.9

The primary outcome measure is the composite score on the Matrics Consensus Cognitive Battery (MCCB). The MCCB composite score is a standardized mean of the seven domain scores. T-scores are standardized to normative data, and have an estimated mean of 50 and SD of 10 in the general healthy population. Data reduction for analysis of neurocognitive testing used the following steps: i) individual neurocognitive test scores at baseline and follow-up were converted to t-scores; ii) t-scores within the pre-specified cognitive domains measured by more than one test were averaged to obtain a domain-specific t-score; and iii) domain-specific t-scores were averaged to create the MCCB composite score. (NCT00505076)
Timeframe: 4 weeks

Schizophrenia Cognition Rating Scale (SCoRS) Score

Intervention	composite score (Mean)
MK-077 8 mg BID	27.9
MK-0777 3 mg BID	31.3
Placebo BID	32.5

The Schizophrenia Cognition Rating Scale (SCoRS) assessed functional capacity. The SCoRS Interviewer Global Rating of function has a range 1 to 10. Higher ratings indicate greater impairment. (NCT00505076)
Timeframe: 4 Weeks (Baseline to End of Treatment)

UPSA(UCSD Performance-Based Skills Assessment) Summary Score

Intervention	SCoRS Score (Mean)
	Baseline	End of Treatment
MK-077 8 mg BID	4.1	4.0
MK-0777 3 mg BID	4.8	4.6
Placebo BID	3.8	3.6

The UCSD Performance-Based Skills Assessment assessed functional capacity. The UPSA Summary Score has a range from 0 to 120. A higher score indicates less impairment. (NCT00505076)
Timeframe: Baseline and end of treatment, a total of four weeks.

Change From Baseline in Acute Insulin Response to Glucose (AIRG)

Intervention	UPSA Summary Score (Mean)
	Baseline	End of Treatment
MK-077 8 mg BID	91.7	90.4
MK-0777 3 mg BID	85.0	86.3
Placebo BID	95.0	96.5

Acute insulin response to glucose (AIRG) was assessed using a Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT), performed at Baseline and at week 8 (study endpoint). Subjects in the Rosiglitazone treatment arm were compared to subjects in the placebo treatment arm on their change in SG between Baseline and week 8. AIRG was calculated from plasma glucose and serum insulin values using the MINMOD Millennium computer program. AIRG measures the acute(0-10 min) beta cell response to a glucose load calculated by the areas under the curve higher than basal insulin values. The AIRG was assessed as the incremental area under the curve (calculated by the trapezoid rule) from 0 to 10 min of the FSIVGTT. (NCT00337350)
Timeframe: baseline, week 8

Change From Baseline in Insulin Sensitivity

Intervention	Units/mL per 10 minutes (Mean)
Rosiglitazone	-151
Placebo	19

Insulin Sensitivity (IS) was assessed using a Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT), performed at Baseline and at week 8 (study endpoint). Subjects in the Rosiglitazone treatment arm were compared to subjects in the placebo treatment arm on their change in IS between Baseline and week 8. SI was calculated from plasma glucose and serum insulin values using the MINMOD Millennium computer program. SI represents the increase in net fractional glucose clearance rate per unit change in serum insulin concentration after the intravenous glucose load (microUnits/mL). (NCT00337350)
Timeframe: baseline, week 8

Change From Baseline on Glucose Utilization (SG)

Intervention	microUnits/mL (Mean)
Rosiglitazone	3.2
Placebo	0.4

Glucose utilization (SG) was assessed using a Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT), performed at Baseline and at week 8 (study endpoint). Subjects in the Rosiglitazone treatment arm were compared to subjects in the placebo treatment arm on their change in SG between Baseline and week 8. SG was calculated from plasma glucose and serum insulin values using the MINMOD Millennium computer program. SG represents the net fractional glucose clearance rate because of the increase in glucose independent of any increase in circulating insulin concentrations above baseline. (NCT00337350)
Timeframe: baseline, week 8

Change From Baseline in Fasting Glucose

Intervention	min^-1 (Mean)
Rosiglitazone	.002
Placebo	-0.01

Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting glucose levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6

Change From Baseline on Fasting Insulin

Intervention	mg/dL (Mean)
Clozapine Treatment With Adjunctive Ziprasidone	5
Olanzapine Treatment With Adjunctive Ziprasidone	-4.5

Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting insulin levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6

Change in Abdominal Fat (DEXA).

Intervention	microIU/L (Mean)
Clozapine Treatment With Adjunctive Ziprasidone	1
Olanzapine Treatment With Adjunctive Ziprasidone	-0.9

A comparison between the ramelteon group and the placebo group of change in abdominal fat measured by a DEXA scan, assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8

Change in Insulin Resistance as Measured by the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR).

Intervention	g (Mean)
Ramelteon	3934.86
Placebo (Sugar Pill)	5120.92

A comparison between the ramelteon group and the placebo group of change in insulin resistance measured by the homeostatic model assessment of insulin resistance (HOMA-IR), assessed at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8

Change in Waist Circumference

Intervention	HOMA score (Mean)
Ramelteon	2.4
Placebo (Sugar Pill)	2.36

A comparison between the ramelteon group and the placebo group in change in waist circumference (measured in cm) measured at Baseline and Week 8. (NCT00595504)
Timeframe: Baseline and Week 8

Article	Year
Maintenance Treatment With Long-Acting Injectable Antipsychotics for People With Nonaffective Psychoses: A Network Meta-Analysis. The American journal of psychiatry, 2021, 05-01, Volume: 178, Issue:5 Topics: Antipsychotic Agents; Aripiprazole; Clopenthixol; Delayed-Action Preparations; Flupenthixol; Fluphen	2021
Increasing antipsychotic dose versus switching antipsychotic for non response in schizophrenia. The Cochrane database of systematic reviews, 2018, 05-11, Volume: 5 Topics: Antipsychotic Agents; Drug Substitution; Fluphenazine; Haloperidol; Humans; Schizophrenia; Treatment	2018
Fluphenazine (oral) versus placebo for schizophrenia. The Cochrane database of systematic reviews, 2018, 06-12, Volume: 6 Topics: Administration, Oral; Akathisia, Drug-Induced; Antipsychotic Agents; Fluphenazine; Humans; Placebos;	2018
Fluphenazine (oral) versus placebo for schizophrenia. The Cochrane database of systematic reviews, 2013, Jul-17, Issue:7 Topics: Administration, Oral; Antipsychotic Agents; Fluphenazine; Humans; Placebos; Randomized Controlled Tr	2013
Fluphenazine (oral) versus placebo for schizophrenia. Schizophrenia bulletin, 2013, Volume: 39, Issue:6 Topics: Antipsychotic Agents; Fluphenazine; Humans; Placebos; Schizophrenia	2013
Fluphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia. The Cochrane database of systematic reviews, 2014, Aug-03, Issue:8 Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Dyskinesia, Drug-Induced; Fluphenazine; Humans; Rando	2014
Fluphenazine decanoate (depot) and enanthate for schizophrenia. The Cochrane database of systematic reviews, 2015, Feb-05, Issue:2 Topics: Administration, Oral; Antipsychotic Agents; Delayed-Action Preparations; Fluphenazine; Humans; Injec	2015
Fluphenazine (oral) versus atypical antipsychotics for schizophrenia. The Cochrane database of systematic reviews, 2016, Jul-02, Volume: 7 Topics: Administration, Oral; Amisulpride; Antipsychotic Agents; Benzodiazepines; Fluphenazine; Humans; Olan	2016
Antipsychotic medication for early episode schizophrenia. The Cochrane database of systematic reviews, 2011, Jun-15, Issue:6 Topics: Antipsychotic Agents; Chlorpromazine; Fluphenazine; Humans; Patient Dropouts; Randomized Controlled	2011
Antipsychotic medication for early-episode schizophrenia. Schizophrenia bulletin, 2012, Volume: 38, Issue:1 Topics: Antipsychotic Agents; Chlorpromazine; Early Medical Intervention; Fluphenazine; Humans; Schizophreni	2012
Depot fluphenazine decanoate and enanthate for schizophrenia. The Cochrane database of systematic reviews, 2005, Jan-25, Issue:1 Topics: Antipsychotic Agents; Delayed-Action Preparations; Fluphenazine; Humans; Randomized Controlled Trial	2005
Risks versus benefits of different types of long-acting injectable antipsychotics. The Journal of clinical psychiatry, 2006, Volume: 67 Suppl 5 Topics: Administration, Oral; Antipsychotic Agents; Fluphenazine; Haloperidol; Health Care Costs; Humans; In	2006
Oral fluphenazine versus placebo for schizophrenia. The Cochrane database of systematic reviews, 2007, Jan-24, Issue:1 Topics: Administration, Oral; Antipsychotic Agents; Fluphenazine; Humans; Placebos; Randomized Controlled Tr	2007
Depot fluphenazine: risk/benefit ratio. The Journal of clinical psychiatry, 1984, Volume: 45, Issue:5 Pt 2 Topics: Administration, Oral; Basal Ganglia Diseases; Clinical Trials as Topic; Dyskinesia, Drug-Induced; Fe	1984
The use of depot neuroleptics: clinical experience in the United States. The Journal of clinical psychiatry, 1984, Volume: 45, Issue:5 Pt 2 Topics: Administration, Oral; Adult; Clinical Trials as Topic; Depressive Disorder; Drug Administration Sche	1984
Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia. Journal of psychiatry & neuroscience : JPN, 1994, Volume: 19, Issue:4 Topics: Antipsychotic Agents; Brain; Dose-Response Relationship, Drug; Fluphenazine; Haloperidol; Humans; Pl	1994
A multidimensional (pharmacokinetic and clinical-biological) approach to neuroleptic response in schizophrenia. With particular reference to drug resistance. Schizophrenia research, 1993, Volume: 8, Issue:3 Topics: Antipsychotic Agents; Biological Availability; Biotransformation; Brain; Dose-Response Relationship,	1993
Dose response of prophylactic antipsychotics. The Journal of clinical psychiatry, 1993, Volume: 54 Suppl Topics: Administration, Oral; Aftercare; Antipsychotic Agents; Combined Modality Therapy; Delayed-Action Pre	1993
Clinical perspectives of some neuroleptics through development and application of their assays. Therapeutic drug monitoring, 1993, Volume: 15, Issue:3 Topics: Antipsychotic Agents; Chemistry, Clinical; Fluphenazine; Humans; Male; Schizophrenia	1993
Depot fluphenazine for schizophrenia. The Cochrane database of systematic reviews, 2000, Issue:2 Topics: Antipsychotic Agents; Delayed-Action Preparations; Fluphenazine; Humans; Schizophrenia	2000
Overview: maintenance therapy in psychiatry: I. Schizophrenia. The American journal of psychiatry, 1975, Volume: 132, Issue:12 Topics: Antipsychotic Agents; Clinical Trials as Topic; Drug Evaluation; Female; Fluphenazine; Humans; Male;	1975
Maintenance antipsychotic drugs do prevent relapse: a reply to Tobias and MacDonald. Psychological bulletin, 1976, Volume: 83, Issue:3 Topics: Antipsychotic Agents; Chlorpromazine; Chronic Disease; Drug Evaluation; Fluphenazine; Humans; Perphe	1976
Maintenance therapy and schizophrenia. The British journal of psychiatry : the journal of mental science, 1975, Volume: Spec No 9 Topics: Acute Disease; Adult; Ambulatory Care; Antipsychotic Agents; Chlorpromazine; Chronic Disease; Clinic	1975
[The combination of psychiatric pharmacotherapy with sociotherapy (author's transl)]. Der Nervenarzt, 1979, Volume: 50, Issue:8 Topics: Adolescent; Adult; Ambulatory Care; Clinical Trials as Topic; Female; Fluphenazine; Humans; Male; Me	1979
[Current status of neuroleptic long term treatment of schizophrenia]. Der Nervenarzt, 1975, Volume: 46, Issue:11 Topics: Ambulatory Care; Antiparkinson Agents; Chronic Disease; Delayed-Action Preparations; Flupenthixol; F	1975
The depot fluphenazines: a reappraisal after 10 years' clinical experience. The American journal of psychiatry, 1975, Volume: 132, Issue:5 Topics: Administration, Oral; Adult; Age Factors; Aged; Ambulatory Care; Basal Ganglia Diseases; Child; Dela	1975
Neuroleptic plasma levels. Schizophrenia bulletin, 1991, Volume: 17, Issue:2 Topics: Antipsychotic Agents; Biological Availability; Chlorpromazine; Fluphenazine; Haloperidol; Humans; Pe	1991
Maintenance medication for schizophrenia: strategies for dose reduction. Schizophrenia bulletin, 1991, Volume: 17, Issue:2 Topics: Antipsychotic Agents; Dyskinesia, Drug-Induced; Fluphenazine; Humans; Schizophrenia	1991
Antipsychotic medication: clinical guidelines for maintenance therapy. The Journal of clinical psychiatry, 1985, Volume: 46, Issue:5 Pt 2 Topics: Administration, Oral; Ambulatory Care; Anti-Anxiety Agents; Antipsychotic Agents; Basal Ganglia Dise	1985
The strategy and value of neuroleptic drug monitoring. Journal of clinical psychopharmacology, 1985, Volume: 5, Issue:5 Topics: Antipsychotic Agents; Chlorpromazine; Chromatography, Gas; Chromatography, Liquid; Fluphenazine; For	1985
Low-dose treatment strategies. The Journal of clinical psychiatry, 1986, Volume: 47 Suppl Topics: Adult; Ambulatory Care; Antipsychotic Agents; Clinical Trials as Topic; Dose-Response Relationship,	1986
The importance of dosage in antipsychotic drug administration--a review of dose-response studies. Psychopharmacologia, 1973, Volume: 29, Issue:3 Topics: Adult; Age Factors; Behavior; Chlorpromazine; Clinical Trials as Topic; Dose-Response Relationship,	1973
Antischizophrenic drugs and brain cholinergic receptors. Affinity for muscarinic sites predicts extrapyramidal effects. Archives of general psychiatry, 1974, Volume: 31, Issue:1 Topics: Animals; Antipsychotic Agents; Butyrophenones; Chemical Phenomena; Chemistry; Chlorpromazine; Dibenz	1974
Side effects of depot fluphenazines. Advances in biochemical psychopharmacology, 1974, Volume: 9, Issue:0 Topics: Agranulocytosis; Barbiturates; Basal Ganglia Diseases; Benztropine; Biperiden; Delayed-Action Prepar	1974
[Differential indication for the use of neuroleptics]. Activitas nervosa superior, 1970, Jan-12, Volume: 12, Issue:1 Topics: Acetaminophen; Chlorpromazine; Drug Synergism; Fluphenazine; Hallucinations; Humans; Imipramine; Met	1970

fluphenazine and Schizophrenia

Research Excerpts

Research

Studies (836)

Authors

Clinical Trials (13)

Trial Overview

Trial Outcomes

Number Who Discontinued Medication Within First 6 Study Months

Change in MATRICS Consensus Cognitive Battery (MCCB)

Change in MATRICS Consensus Cognitive Battery Composite Score Change

Change in SCoRS Interviewer Global Rating

Change in SCoRS Interviewer Global Rating

Change in UCSD Performance-Based Skills Assessment (UPSA) Summary Scores

Change in UCSD Performance-Based Skills Assessment (UPSA) Summary Scores

Composite MATRICS Consensus Cognitive Battery Score

Schizophrenia Cognition Rating Scale (SCoRS) Score

UPSA(UCSD Performance-Based Skills Assessment) Summary Score

Change From Baseline in Acute Insulin Response to Glucose (AIRG)

Change From Baseline in Insulin Sensitivity

Change From Baseline on Glucose Utilization (SG)

Change From Baseline in Fasting Glucose

Change From Baseline on Fasting Insulin

Change in Abdominal Fat (DEXA).

Change in Insulin Resistance as Measured by the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR).

Change in Waist Circumference

Reviews

Trials

Other Studies

Authors	Studies
Nudelman, A	1
Gil-Ad, I	1
Shpaisman, N	1
Terasenko, I	1
Ron, H	1
Savitsky, K	1
Geffen, Y	1
Weizman, A	3
Rephaeli, A	1
Socco, S	1
Jhawar, A	1
Riddle, MA	1
Kamali, M	1
Zarghami, M	1
Azizi, M	1
Elyasi, F	1
Misawa, F	1
Fujii, Y	1
Takeuchi, H	1
Okada, Y	1
Inada, K	1
Akazawa, M	1
López-Herrero, F	1
Contreras-Díaz, M	1
Sánchez-Vicente, JL	1
Crosta, CM	1
Hernandez, K	1
Bhattiprolu, AK	1
Fu, AY	1
Moore, JC	1
Clarke, SG	1
Dudzinski, NR	1
Brzustowicz, LM	1
Paradiso, KG	1
Firestein, BL	1
Ostuzzi, G	1
Bertolini, F	1
Del Giovane, C	1
Tedeschi, F	1
Bovo, C	1